BioVie (BIVI) investor relations material

Executive overview

• Presentation focused on two lead drug assets: bezisterim for neurodegenerative and inflammatory CNS conditions, and BIV201 for end-stage liver disease ascites.

• Bezisterim has shown efficacy in reducing inflammation, reversing insulin resistance, and improving muscle control and cognition in clinical trials for Parkinson's and Alzheimer's.

• BIV201 demonstrated over 50% reduction in ascites fluid buildup, leading to early trial termination and plans for a phase III registration trial pending $25M funding.

• Company received a $13M grant for a long COVID trial, the only such grant for a therapeutic targeting CNS symptoms, with top-line data expected by year-end.

• Both Parkinson's and long COVID trials are fully enrolled, with imminent data readouts expected in June and by the end of summer, respectively.

Clinical development and pipeline strategy

• Phase IIb Parkinson's trial aims to show bezisterim's efficacy in early-stage patients, with top-line data expected by end of June.

• Long COVID trial is enrolling 100 patients at major academic centers, with potential for accelerated approval or emergency use if results are positive.

• Bezisterim is positioned as a platform molecule for multiple CNS indications, with additional related molecules in the pipeline.

• BIV201 is being spun out into a new company, Option Therapeutics, to raise funds for a pivotal trial.

• Biomarker development includes DNA methylation and alpha-synuclein, with ongoing advocacy for FDA recognition.

Market opportunity and financial outlook

• Parkinson's indication for bezisterim estimated as a $3B–$5B annual U.S. sales opportunity; long COVID could exceed $10B annually.

• Company is trading at half its cash value, with a market cap of $10M, and is considered undervalued relative to its pipeline and near-term catalysts.

• Management and board are significant shareholders, reinforcing alignment with investor interests.

• Multiple pharma companies have expressed interest, pending positive clinical data readouts.

• Investors are encouraged to track clinical readouts and the Option Therapeutics spin-off as key milestones.